🏆 Deal of the Week · CW 17/2024
CN Bio raised USD 21 million in a Series B round; the post-money valuation was not disclosed. The round was backed by CN Innovations and Bayland Capital. The deal was recognised as Venionaire DealMatrix Deal of the Week for KW 17/2024.
CN Bio — key deal facts
| Company | CN Bio |
| Founded | 2009 |
| Headquarters | Cambridge, United Kingdom |
| Amount raised | USD 21M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | CN Innovations Bayland Capital |
| Sectors | Biotechnology |
Who invested in CN Bio?
The Series B was funded by CN Innovations and Bayland Capital. CN Innovations is the founding shareholder of CN Bio, making its continued participation a signal of institutional confidence in the company's commercial trajectory. The presence of Bayland Capital alongside the founding investor suggests a combined strategic and growth-oriented rationale for the round.
What does CN Bio do?
CN Bio is a biotechnology company headquartered at Cambridge Science Park, Cambridge, United Kingdom. Founded in 2009, it develops organ-on-a-chip microphysiological systems designed to improve the accuracy and efficiency of preclinical drug discovery by generating human-specific efficacy and safety data. Its primary product line is the PhysioMimix® suite, which includes single- and multi-organ microphysiological systems, 3D-validated cells, consumable plates, and contract research services. The company operates under the legal name CN Bio Innovations Limited.
CN Bio valuation & multiples
No existing multiples analysis was provided for this deal. Because CN Bio's post-money valuation remains undisclosed, EV/Sales and EV/EBITDA multiples cannot be calculated from verified data. Readers seeking comparable transaction multiples for the biotechnology and organ-on-a-chip sector are invited to consult the relevant sector multiples pages on DealMatrix.
Explore the benchmarks: Series B.
Frequently asked questions
How much did CN Bio raise in its Series B?
CN Bio raised USD 21 million in its Series B round, announced in April 2024.
What is CN Bio's valuation?
CN Bio's post-money valuation was not disclosed as part of this Series B funding announcement.
Who invested in CN Bio?
The Series B was funded by CN Innovations and Bayland Capital.
When was CN Bio founded and where is it based?
CN Bio was founded in 2009 and is headquartered at Cambridge Science Park, Cambridge, United Kingdom.
Source: original announcement — read the full report.